With influenza vaccination rates in the United States recently exceeding 45% of the population, it is important to understand the impact that vaccination is having on influenza transmission. In this study, we used a Bayesian modeling approach, combined with a simple dynamical model of influenza transmission, to estimate this impact. The combined framework synthesized evidence from a range of data sources relating to influenza transmission and vaccination in the United States. We found that, for seasonal epidemics, the number of infections averted ranged from 9. 
Influenza presents a significant public health challenge (1, 2) . In temperate regions, seasonal epidemics occur every year during the winter months and cause widespread morbidity and mortality (2) . Less frequently, pandemics are sparked by the emergence of novel influenza viruses of zoonotic origin that can spread efficiently between people (3, 4) .
Vaccination is the mainstay of public health interventions to control influenza (5) . However, some of the most vulnerable, such as the elderly and the immunocompromised (6, 7) , tend to fail to raise a protective immune response to influenza vaccination (8, 9) . Nevertheless, the impact of vaccination exceeds the direct protection of those receiving it: By reducing opportunities for transmission, a vaccination program can also engender indirect protection-the effect by which vaccinated and unvaccinated individuals are protected as a result of reduced opportunities to acquire infection from those who have been immunized (10) . There is a range of empirical evidence for substantial indirect protection arising from influenza vaccination (11) (12) (13) (14) .
Recent studies in different country settings have used combined mathematical and statistical modeling frameworks to show how such indirect protection could be efficiently promoted by expanding coverage to include school-aged children, who are significant transmitters of influenza (15) (16) (17) . In recognition of these potential benefits, influenza vaccination policy in the United Kingdom has recently been expanded to include this age group.
The United States offers an example of a country currently at moderate vaccination coverage across all age groups. Since 2010, annual influenza vaccination has been recommended for all individuals aged 6 months or older (18, 19 ). An estimated 45% of the population was vaccinated during the 2012-2013 season (20) . It would be of great value to understand the impact of vaccination at such levels. In particular, how much influenza is being averted annually, due to both direct and indirect effects of vaccination?
Two recent studies undertook detailed analyses of various data sources to assess the direct effects of vaccination on influenza-associated hospitalizations and medically attended illness (21) as well as on mortality (22) in the United States. In this study, we built on this work by incorporating the indirect effects of vaccination on influenza transmission. We used national data (from 2005 onward) on vaccination coverage, vaccine effectiveness (VE), and laboratory-confirmed influenza hospitalizations. Using a mathematical model of influenza transmission, we estimated, for each season, the "counterfactual" epidemic that might have occurred in the absence of vaccination. From this we estimated the number of infections averted, owing to both direct and indirect effects of large-scale vaccination uptake.
METHODS

Data sources
Incidence: influenza-associated hospitalizations. The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts active surveillance for laboratory-confirmed hospitalizations associated with influenza for both children and adults in 60 counties over 10 states in the United States and has a catchment population of approximately 22 million people. We used monthly data for each influenza season from 2005 onward for 4 different age groups (6 months to 4 years, 5-19 years, 20-64 years, and ≥65 years) and spatially aggregated these data over the United States. As indicated on the lower row of Figure 1 , this period includes the H1N1 pandemic, which began in April 2009 and, after 2 distinct epidemic "waves," subsided in early 2010. For the purpose of this analysis we concentrated on the second ("fall") wave, because this was the wave during which vaccination was deployed.
To estimate the overall incidence of influenza from FluSurv-NET hospitalization reports, it is necessary to estimate what proportion of influenza cases, from each age group, were hospitalized for influenza, what proportion were hospitalized at a facility participating in the FluSurv-NET network, and finally what proportion of these hospitalized cases tested positive in virological testing for influenza. For these parameters we borrowed from previous work (23, 24) that estimated (for example) that during the 2009 pandemic, there were 406 symptomatic cases aged 20-64 years for every hospitalized case in this age group that was reported through FluSurv-NET. We used different multipliers for pandemic and seasonal epidemics, as illustrated in the Web Appendix (available at https://academic.oup.com/aje) (Web Figure 1) . As described below, these factors lend themselves readily to incorporation in a simple probabilistic model for case ascertainment through this surveillance system.
Vaccine uptake. Estimates of monthly national vaccine coverage, in each of the 4 age groups, were taken from the National Health Interview Survey (NHIS) for the influenza Figure 1 shows the dynamics of vaccination coverage in relation to those of the epidemic, for each of the seasons concerned in this study. We employed a model structure that kept track of changing vaccination coverage during the course of an epidemic. Vaccine effectiveness. Field studies typically measure VE by recruiting outpatients with medically attended acute respiratory illness for virological testing for influenza and ascertaining vaccination history. VE is then expressed as an odds ratio for being vaccinated among influenza-confirmed infections versus test-negative controls (as in Foppa et al. (25) (8), respectively. We fitted a beta distribution to this data, fitting the shape and scale parameters to capture the point estimates and uncertainty in VE. The resulting distributions, used as inputs to the model, are shown in Web Figure 2 .
Transmission model structure
We simulated each season separately, treating each as an independent epidemic wave with its own initial conditions and parameters to be fitted. For each season we used a deterministic, compartmental model whose structure is summarized in Figure 2 . In this framework we assumed conservatively that a vaccine reduces susceptibility but-in the event of acquiring infection-does not reduce infectiousness. The direct effect of vaccination thus arises from the factor c diminishing susceptibility in the bottom row of Figure 2 (that is, assuming a "leaky" vaccine (27) ). In turn, by reducing the numbers of infected cases, this has the effect of reducing the force of infection λ, thus giving rise to the indirect effect of vaccination. We also allowed for a delay between vaccination and the development of vaccine-induced immunity in an individual: on average, a delay of 2 weeks (represented by w in Figure 2 ).
The model was spatially aggregated over the United States but stratified into 4 age classes, consistent with FluSurv-NET data (6 months to 4 years, 5-19 years, 20-64 years, and ≥65 years). To parameterize "mixing" between the age groups, we used data from diary-based contact studies from countries in Western Europe (28) , assuming that-for the relatively broad age strata being employed here-similar contact patterns also apply in the United States.
We also made the following simplifying assumptions: All infected cases had the same per-contact infection rate β (to be estimated) that did not vary by age. In addition, for simplicity, we did not distinguish different components of the influenza vaccine, that is, between influenza A/H1, A/H3, and influenza B. Finally, owing to a lack of data on the relative transmission potential of symptomatic and asymptomatic infection, we did not aim to distinguish these states in the model. Instead, the transmission rates inferred from this model effectively represented an average across these states. Governing equations for the model are provided in the Web Appendix.
Parameter inference
The set of model inputs are denoted by the vector θ, composed of the following (also, for reference, listed in Web Table 1 ):
1. The transmission rate per contact between an infectious and a susceptible individual in the absence of vaccination, β. 2. The reduction in susceptibility c i due to vaccination in age group i. In the model this represents a reduction in the probability of infection per unit time of contact between a susceptible and an infectious individual. 3. The initial susceptibility S i (0) in the age group i prior to the epidemic and in the absence of any vaccination. It is important to account for any existing immunity in the different age groups (for example, through past infection or vaccination). Neglecting to do so erroneously attributes all immune protection to the vaccination program alone, thus overestimating the impact of vaccination.
Here, we assumed that prior immunity is completely protective from infection. 4. The rate of recovery γ, assumed to be the same for all age groups. 5. The probability p i that a symptomatic case in age group i is reported through FluSurv-NET. Figure 2 . Schematic illustration of the model structure for a single influenza season (epidemic wave). For clarity in illustrating the overall structure, the model is shown here without age stratification (see governing equations in the Web Appendix for the incorporation of age classes). Here, S is the number of individuals susceptible to infection; I is the number infected and infectious; and R is the number who are recovered and immune. Individuals are vaccinated at a per-capita rate r(t), which varies from month to month and is inferred from the data on vaccination coverage. λ is the "force of infection," taking account of the prevalence of infection (
) at any given time. In the presence of age structure, the force of infection additionally incorporates a matrix representing "mixing" between the different age groups (see Web Appendix for details). Once vaccinated, we assume that individuals take on average 2 weeks to develop vaccine-induced immunity. Thus, in this diagram, the top row represents those who are unvaccinated, and the middle row represents those who have received vaccination but are not yet immune. Upon acquiring vaccine-induced immunity at a per-capita rate w, these individuals subsequently enter the bottom row. Only those in this latter state have the benefits of vaccine-induced immunity, susceptibility diminished by a factor c.
For a given set of parameters θ and data D we have, for the posterior distribution π in a Bayesian framework,
where q(θ) is the "joint prior distribution" (here assuming independent priors), representing the information available on θ independently of the model, and
is the classical likelihood of the data given the parameters θ. The objective of the analysis is to sample from the posterior distribution π. We next describe individually each of these components in equation (1).
Prior distribution. For the probabilities p i , we interpreted these as the inverse of the hospitalization-to-case "multipliers" developed in Reed et al. (23) . To incorporate uncertainty in the multipliers, we assumed p i to follow a beta-distribution, inferred from the point and uncertainty estimates for the multipliers. The raw multipliers correspond hospitalizations to symptomatic cases. To adjust these additionally to account for asymptomatic cases (since the transmission model averages across symptomatic and asymptomatic cases), we increased the multipliers by a factor k, reflecting the assumption that 67% of infections are symptomatic (95% credible interval (CI): 58, 75) (29)). Further details, and resulting distributions for the probabilities p i are shown in Web Figure 1 . For remaining parameters, we took uniform (uninformative) priors, with the bounds shown in Web Table 1 .
Likelihood. For a given parameter vector θ, we evaluated the likelihood as
L D Pr i t Pr i
Reported FluSurv-NET incidence in age class , month Reported VE in age-class , 2
where Π i represents a product over the age groups i. For the first term of this expression, we used a simple "observation" model for how incidence maps to hospitalizations. Suppose parameter set θ yields a simulated epidemic with n i (t) incident cases in month t and age class i (aggregated over vaccination status). Resulting FluSurv-NET notifications thus follow a binomial distribution:
Pr Reported FluSurv-NET incidence in age-class ,
where p i is as defined above, and the first term on the righthand side of equation (2) is obtained through a product of these probabilities over i and t. Next, as noted above, c i is the reduction in the probability of infection per unit time of contact between a vaccinated susceptible individual and an infectious individual. As such, c i is not strictly equivalent to field estimates of VE; whereas c i relates to each infectious contact, VE is taken over the course of the whole epidemic. For a simulated epidemic, therefore, we take the ratio of attack rates among vaccinated and unvaccinated individuals to find a simulated VE. The choice of c i is then guided by agreement between this and the measured VE. This is the role of the second likelihood term in equation (2) above.
In particular, we assumed that vaccination each year is random with respect to prior immunity, and thus does not depend on S i (0). Suppose that the simulated epidemic has an attack rate AR i (0) among the unvaccinated in age group i, and likewise for AR i
(1) among the vaccinated, irrespective of prior immunity. Then the "simulated" VE in age group i was calculated as
reflecting how VE is measured in practice, with the notation VS emphasizing that this is a simulated VE. Thus to calculate the associated likelihood, if f i is the probability distribution for age group i (Web Figure 2) , we evaluated ( )
Sampling from the posterior distribution. We employed a Markov Chain Monte Carlo (Metropolis-Hastings) procedure (30) . From the resulting series of values for outcomes of interest (including cases averted by vaccination), we extracted the median and the upper and lower 2.5th percentiles. Further details on the implementation of this procedure are given in the Web Appendix. Figure 3 shows the separate data fits to the trajectories of each epidemic from the 2005-2006 influenza season to the 2012-2013 season under the "best-fitting" parameter set for each season (i.e., arising from the mode of the posterior distribution), illustrating that the model mostly captured the transmission dynamics in each of the age groups (see also Web Table 1 for log-likelihoods corresponding to these parameter sets). Figure 4 shows the underlying estimates for the fundamental parameters in the model. The effective reproduction number (both in the presence and absence of vaccination) was calculated by constructing the next-generation matrix for this model after van den Driessche and Watmough (31) , with further details given in the Web Appendix. Despite 2009-2010 being a pandemic wave, the model fits indicated some existing immunity in those aged 5 years or older, which may have arisen in part from the initial "spring" wave of the pandemic that occurred in April 2009. However, this epidemic is also unique in the age group ≥65 years being estimated to have the lowest susceptibility of any age group. Indeed, this is in agreement with evidence for the existence of protective, prior immunity in this age group, thought to arise from past exposure to related viruses circulating before 1957 (32, 33). As described in the Web Appendix, the reproduction number is determined by infectiousness (β) and the infectious period (γ) as well as by susceptibility. Thus, although the pandemic virus shows the highest population susceptibility, its reproduction number in the absence of vaccination is sometimes exceeded by viruses in other seasons. Web Figure 3 additionally shows comparisons between prior (data) and posterior (simulated) estimates for VE, for each season and age group. Figure 5A shows the absolute numbers of infections averted in each season, resulting from these parameters. For comparison, the figure also summarizes findings for the direct effects of vaccination (gray curve), estimated as described in the Web Materials. The difference between the 2 curves can be regarded as representing approximately the cases averted due to indirect effects alone. In nonpandemic years, numbers averted varied from a minimum of 9.6 million (95% CI: 8. Although we have not explicitly distinguished symptomatic and asymptomatic cases in the model, under the assumptions described above, approximately two-thirds of these numbers averted would be symptomatic cases. Impact according to age group is shown in Web Tables 2 and 3 ; for example, in general the youngest (6 months to 4 years) and oldest (≥65 years) tended to show the greatest percent reductions in attack rate. Figure 4 illustrates the extent to which seasons can vary in their underlying epidemiologic parameters, in ways that shape the impact of a vaccination program. For example, a weak vaccination program applied to a large epidemic (arising, for instance, from high susceptibility) may still result in many cases averted, owing to the size of the epidemic. As context, Web Figure 4 shows the size of each season as measured by the cumulative cases reported through FluSurv-NET. To adjust for these differences between seasons, Figure 5B plots the estimated fraction of cases averted-that is, the percentage reduction (by vaccination) of the final attack rate. Overall, during seasonal epidemic years, results suggested that vaccination has prevented approximately 30% to 45% of cases per season. Once again, due to the timing of the pandemic wave, the fraction averted in 2009-2010 was a special case. the effectiveness and coverage of the vaccine itself. We aimed to combine these factors in a parsimonious modeling framework, synthesizing different sources of evidence to capture the effect of the vaccination in the United States over a period of 8 years. Our analysis showed how, given sufficient coverage, a vaccination program can affect influenza transmission. In particular, capturing both direct and indirect effects of vaccination, we estimated that annual vaccination in the United States averted 135 million cases of influenza from 2005 to 2013. It is notable that such impact is possible with the use of influenza vaccines that have a moderate level of coverage and a measured VE of typically 60% or less (34) , which would also appear moderate, particularly in the context of other vaccines (e.g., for measles) (35, 36) . However, an important point is that, in comparison with these diseases, the effective reproduction number of influenza is relatively low, even in the absence of vaccination. Our estimates for this quantity (Figure 4) are consistent with the range of 1-2 typically found in the literature (37, 38) . On the population level, therefore, sufficiently wide deployment of a vaccine with even moderate VE has the potential to substantially affect the transmission of influenza. This phenomenon is especially apparent in Figure 5 , where indirect effects (the difference between the 2 curves) account for a substantial proportion of cases averted, indeed greater than direct effects alone (gray curve). Such effects notwithstanding, increased coverage-as well as the development of vaccines with improved effectiveness (especially in the elderly)-will substantially improve the public health impact of influenza vaccination. Future immunization enhanced in these ways might even interrupt transmission altogether (bringing the reproduction number below 1).
RESULTS
Our results also illustrate the factors, other than vaccination rates, that can strongly influence the size of seasonal epidemics. Two examples are the 2011-2012 and 2012-2013 seasons, which were comparable in their vaccination coverage and transmission potential (Figure 4) . However, the 2012-2013 season was notably large in its magnitude (39) , and 2011-2012 was not (40) (Figure 1 ). Our results suggest that, rather than vaccination impact, a major difference between these 2 epidemics was the level of existing immunity in the population ( Figure 4B) . Notably, the 2010-2011 season was preceded by 2 years of virus circulation without vaccine-altering antigenic change in either influenza H1 or H3 (Web Table 4 ). Together with ongoing vaccination coverage in these years, the population immunity thus accumulated could account for the low susceptibility in the 2010-2011 season. One implication for vaccine impact is that epidemics with higher levels of existing immunity in the population would tend to show a lower impact attributable to vaccination. More broadly, comparing across epidemic seasons, these results illustrate that-although increasing vaccination rates may be expected to diminish the sizes of influenza epidemics over time-in practice, the natural variability in other factors (existing immunity, virus infectiousness, etc) can play an equally strong role. Even in such changing circumstances, our results suggest that vaccination nonetheless had a substantial effect on transmission in the United States between 2005 and 2013.
As with any analysis of retrospective surveillance data, there are some limitations to note. First, to describe contact patterns between different age groups, we chose to approximate conditions in the United States with contact patterns in the United Kingdom, for which data exist. Nonetheless, while it would be valuable to validate this assumption once data are available for the United States, we do not expect qualitative features of the mixing matrix (including individuals mixing preferentially with those in their own age groups and the most mixing occurring between school-aged children) to differ substantially between the United States and the United Kingdom. In the absence of controlled studies of influenza transmission in the population, individualbased simulations (which offer explicit demographic and population-mixing scenarios (41)) may offer helpful comparisons with the findings in this study.
Second, as the parameter inputs to the model, we used "multipliers" to relate influenza hospitalizations to cases in the community. Our work illustrates how multipliers naturally play a central role in capturing the relationship between reported data and the underlying epidemic process. However, estimated through dedicated studies combining household telephone surveys and audits of hospitalization records, these multipliers are so far available only from a handful of studies (23, 24) . Epidemics may vary from year to year in their severity in different age groups; for example, the 2012-2013 season was particularly severe in the elderly (39) . While Figure 4B suggests that this arose from elevated susceptibility in this season and age group, it could equally arise from a change in hospitalization rates. Accordingly, repeated studies to estimate multipliers across several seasons will allow a systematic assessment of how these hospitalization rates vary through time. Moreover, while our work focuses on hospitalization data, a valuable extension for future work would be to also capture milder forms of influenzarelated illness, potentially incorporating broader sources of data, such as virology and syndromic surveillance. Such estimations could be especially helpful for addressing the economic implications of influenza vaccination.
Third, for simplicity, we aggregated H1 and H3 subtypes of influenza A as well as influenza B in this analysis. With most influenza epidemics being typically dominated by one or the other subtype, we may expect this assumption to have only a limited effect as long as each seasonal epidemic is treated separately, as we have done here. Nonetheless, a more detailed model resolving these antigenic variants would benefit from more finely resolved data resolving type and subtype, particularly for hospitalization multipliers, and VE data (at present disaggregated only from the 2010-2011 season onwards).
Fourth, the dynamical model entailed several simplifying assumptions that could be relaxed with improved data in future work. For example, we did not attempt to distinguish symptomatic and asymptomatic infection in the model, with the transmission parameter β essentially representing an average across these states. To address this simplification would require better data, not only on the proportion of infections becoming symptomatic but also on the relative infectiousness of asymptomatic infections. Such data would also permit a better understanding of the extent to which vaccination reduces not just symptomatic illness (as addressed by current VE studies) but also infection. For simplicity, our approach assumes both effects to be the same. Moreover, we assumed some underlying parameters to be fixed regardless of age. Future work would benefit in particular from a better quantification of how the mean infectious period (γ) and the infectious dose per contact (informing β) tend to vary between children and adults. Also, to avoid overfitting the model, we assumed a simplified effect of vaccination, in which we assume that it reduces susceptibility alone by a factor c. This is likely to be conservative; there may be some additional vaccine effect on infectiousness. With currently available data, it is difficult to separate these effects empirically. To do so, there is a need for better correlates of influenza transmission potential (42) . Additionally, we have not considered the potential effects of climatic and other seasonal factors (43) (44) (45) (46) . BRFSS is a telephone survey while the NHIS is a probability sample of households, and they therefore use different weighting procedures to reflect the different survey designs.
In conclusion, vaccination in the United States has had a significant impact on morbidity and mortality associated with influenza. In assessing the impact of vaccination, transmission models offer a helpful tool with which to bring together diverse sources of data and to systematically disentangle the various factors involved in shaping an epidemic. Our results illustrate how a vaccination program can, in addition to directly mitigating morbidity and mortality, also reduce transmission. In so doing, vaccination can offer a powerful tool for controlling influenza.
